FBE- Moleküler Biyoloji-Genetik ve Biyoteknoloji Lisansüstü Programı - Yüksek Lisans
Bu koleksiyon için kalıcı URI
Gözat
Sustainable Development Goal "Goal 9: Industry, Innovation and Infrastructure" ile FBE- Moleküler Biyoloji-Genetik ve Biyoteknoloji Lisansüstü Programı - Yüksek Lisans'a göz atma
Sayfa başına sonuç
Sıralama Seçenekleri
-
ÖgeEvolutionary engineering and physiological analysis of antimycin-a resistant Saccharomyces cerevisiae(Institute of Science and Technology, 2018-06-07) Topaloğlu, Alican ; Çakar, Zeynep Petek ; 521151101 ; Molecular Biology - Genetics and BiotechnologySaccharomyces cerevisiae is a well known eukaryotic model organism in terms of its clearly known genetic and metabolic basis and the ease of cultivation. Its genome was fully sequenced at 1996 and it was the first eukaryotic organisms which the genome was fully sequenced. Additionally, S. cerevisiae genome has high homology genes with the human genome. Furthermore, it is also a good model organism to study mitochondrial functions because of its special properties. Most of the discoveries about mitochondria were found on S. cerevisiae model organism. Most importantly, it is a facultative microorganism which can survive under mitochondrial dysfunction and it has several survival mechanisms against mitochondrial DNA mutations. Mitochondria is an organelle which has the main function of producing energy by oxidative phosphorylation. In addition to this function, it has also other responsibilities like thermogenesis, apoptosis, lipid and sterol synthesis and calcium storage. It is a double-membrane organelle and includes its own mitochondrial DNA (mtDNA) and ribosomes which are structuraly different than cytoplasmic ones. As its structure and functions, it is more likely to prokaryotic microorganism. Functional disorders of mitochondria might cause mitochondrial diseases which are observed in the most energy-requiring systems, mainly nervous and muscle system. Those disorders typically cause cardiovascular and neurodegenerative disorders, vision and hearing loss, diabetes, kidney and liver failures. Although many discoveries were made on the pathogenesis of mitochondrial disorders in the last two decades, there are still no effective treatments to cure those diseases. Most of the genetic and functional information about mitochondria was obtained by the studies with S. cerevisiae as the model organism. Today, most of the mitochondrial diseases caused by genetic mutations are researched on S. cerevisiae models by using recombinant DNA technologies and rational metabolic engineering techniques. However, such experimental design has some limitations, such as requiring detailed genetic background knowledge, rejection of recombination by the organism and obtaining unexpected phenotypic results. Because of these limitations, inverse metabolic engineering has been introduced as an alternative approach. In light of this information, in the present study, it was aimed to obtain antimycin-A resistant S. cerevisiae mutants by evolutionary engineering, an inverse metabolic engineering strategy, and to complete physiological analyses that are the first steps to enlighten the molecular basis of this resistance. Antimycin-A is a mitochondrial complex III inhibitor which binds to bc1 complex and inhibits electron transfer. It is the analog of quinone and binds Qi site of the bc1 region (Quinone binding site) Binding of antimycin-A to this site blocks further electron transfer from Qo site and electron transfer to complex IV is stalls. As a result, cells cannot produce enough energy via mitochondrial oxidation and are obliged to find alternative metabolicpathways to survive. Additionally, antimycin-A cause increased Reactive Oxygen Species (ROS) generation by disrupting redox reactions on the mitochondria. Other than antimycin-A, there are various mitochondrial inhibitors such as atpenin, oligomycin, stigmatellin or cyanide which are widely used in research. While deciding the mitochondrial inhibitor among others, many factors were considered. Thus, considering the high affinity to bind mitochondrial complex III, the power of inhibition at low concentrations and safety of use, it was decided to use antimycin-A as the mitochondrial inhbitior in this study. In this study, antimycin-A resistant mutants were selected successfully from both reference strain and EMS-mutagenized reference strain population. As the selection method, gradually increasing stress level application protocol was used in succesive batch cultures under respirative conditions to make cells dependent on mitochondrial functioning. After 52 passages, antimycin-A concentration was increased to 6.6 nM and mutant individuals were randomly picked from the final populations. Twelve mutants were chosen from the reference strain selection and 15 mutants were chosen from the EMS-mutagenized reference strain population. After those mutants were screened at different antimycin-A concentrations, two mutants with the highest resistance levels were chosen. It was observed that mutant individuals obtained from the reference strain selection were resistant to 15 nM antimycin-A, while mutants obtained from the EMS-mutagenized reference strain population were resistant to 50 nM antimycin-A. This study, based on the literature information, is the first one where antimycin-A resistant S. cerevisiae mutants were obtained by evolutionary engineering strategy. To determine whether the gained antimycin-A resistance was permanent or not, genetic stability test was applied. Except for one mutant individual obtained from the reference strain selection, all resistant mutants tested were genetically stable. Additionally, antimycin-A resistant mutant population obtained from the reference strain selection might indicate possible mutagenic effects of antimycin-A. Within the frame of physiological characterization experiments, cross-resistance analyses results revealed that, antimycin-A resistant mutants were also cross-resistant to caffeine, propolis, coniferyl aldehyde and ethanol. Similarly, mutants resistant to these chemicals except for the ethanol-resistant mutant were also found to be cross-resistant to antimycin-A in a previous study. This implies some similar molecular stress resistance mechanisms between these mutants. Resistance to ethanol is also an expected result, because the selection procedure was applied by using ethanol as the sole carbon source. In this study, antimycin-A resistant S. cerevisiae mutants were obtained by evolutionary engineering strategy and the physiological characterization experiments were performed. For further studies, genomic and transcriptomic analyses could be performed to identify alternative pathways which by-pass the effects of the nonfunctional mitochondrial complex, and possible pharmaceutical targets could be identified.
-
ÖgeInvestigation of antimicrobial resistance in wild-type and stress-resistant Saccharomyces cerevisiae strains(Institute of Science and Technology, 2018-06-07) Ismaeel, Riziq Nahidh ; Çakar, Zeynep Petek ; 521151116 ; Molecular Biology – Genetics and BiotechnologyFungi are organisms that live in various habitats like air, soil and water. Some species live as symbionts and some are parasites. Fungi kingdom consists of mushrooms, molds and yeasts. They all contain rigid cell walls. Yeast are spread worldwide, they are mostly in the phylum ascomycota, and only a few are within the phylum Basidiomycota. There is a high number of economically important types of ascomycete yeasts. These types are commonly used in bread, wine, and beer production; and are selected from Saccharomyces cerevisiae strains. Saccharomyces cerevisiae is a eukaryotic unicellular microorganism. It has a completely sequenced compact genome which makes it a suitable microorganism for easy manipulation of the genome and also ease of cultivation. In this study, ethanol-resistant, coniferyl aldehyde-resistant, caffeine-resistant, propolis-resistant and antimycin-resistant mutant S. cerevisiae strains which were previously obtained by inverse metabolic engineering strategy, were analyzed against different antimicrobials and possible relations between resistance to those antimicrobials were investigated. For this analysis, spot assay method was applied to reference strain (905) and mutant strains under respirative and fermentative conditions against rapamycin, erythromycin, kanamycin and antimycin-A antimicrobials. Antibiotics are generally known and referred to as a subset of anti-infective agents which are derived from bacterial or fungal sources that are used to treat bacterial infections. Antibiotics are generally used medically to treat or prevent bacterial infections. Most antibiotics inhibit the replication or completely kill bacteria. The name 'antimicrobial' is a general term for any compound that inhibits some vital functions or kills microorganisms including chemicals such as antibiotics, antifungal agents, antivirals, and antiseptics. Fungi and viruses may also pose some risks to humans and are targeted by antifungals and antivirals, respectively. Rapamycin is a macrocyclic antibiotic. It is produced by the soil bacterium Streptomyces hygroscopicus found on Easter Island soil. Rapamycin was discovered as a potent antifungal agent, but initially, it exhibited an undesirable and immunosuppressive effect, leading to its development as a clinically useful drug. Rapamycin is the inhibitor of Target of Rapamycin (TOR) pathway. This pathway has important roles such as nutrient sensing, chronological aging, apoptosis and energy metabolism. There is a recent discovery which states that the mTOR inhibitor rapamycin can extend the lifespan of mammals which has created great excitement, as it represents the first demonstration of the pharmacological extension of maximum life in a mammalian species. Since then, rapamycin effects on the lifespan of mammals have been confirmed by some additional studies. Kanamycin is mostly known and referred as kanamycin (A). It is an aminoglycoside bactericidal antibiotic which is found in oral, intravenous, and intramuscular forms. It is used to treat and cure a wide range of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus, and its mostly and commonly used form is kanamycin sulfate. Aminoglycosides function by binding to the bacterial 30S ribosomal subunit and causing misreading of t-RNA. By this way, the bacterium cannot synthesize the proteins vital for bacterial growth. Aminoglycosides are generally used against infections of aerobic, gram-negative bacteria such as Pseudomonas, Acinetobacter, and Enterobacter. Additionally, some mycobacteria are susceptible to aminoglycosides, including bacteria that cause tuberculosis. Infections caused by gram-positive bacteria can also be treated with aminoglycosides, but other antibiotics are more potent and less harmful to the host. Erythromycin is a bacteriostatic macrolide antibiotic produced by Streptomyces erythreus. By binding to the 50S ribosomal subunit, it inhibits protein synthesis. The binding to the 50S ribosomal subunit inhibits peptidyl transferase activity and interferes with the translocation of amino acids during the cycling and coupling of proteins. Erythromycin is released from the bacterial cell membrane and is reversibly attached to the 50S subunit of the bacterial ribosome. This prevents bacterial protein synthesis. Depending on the concentration of the drug, erythromycin may exhibit bacteriostatic or bactericidal action in the infection site and the sensitivity of the related organism. Additionally, erythromycin may enhance the actions of other drugs by the inhibition of microsomal metabolism, leading to toxicity of these other medications. Erythromycin is available in the form of different esters, including erythromycin estolate, erythromycin lactobionate, erythromycin ethylsuccinate, and erythromycin gluceptate. Antimycin-A is an antifungal produced by Streptomyces species. It is the mitochondrial complex III inhibitor. Antimycin binds closely to a pocket in 1 of 5 of the major electron transport proteins. Antimycin binds at the stage where ubiquinol, referred to as (coenzyme Q,) which usually binds to produce electrons to the level of (O2) that is bound to a close iron-containing enzyme. This explains why the electron transporter is blocked at some stages, the bound oxygen is exchanged to superoxide, a very reactive form of oxygen. Antimycin interacts specifically with the complex system of protein structures related to the electron movement. Biochemists make use of this specific binding of antimycin to avert the electron flow and to investigate the chemical details of aerobic respiration. With these investigations, significant information has been revealed about how antimycin adds at the enzyme level, down to the molecular level and the specifics on how the side chains on the antimycin can impact and influence the electron movement at the protein stage. Antimycin is an active ingredient in Fintrol®, a registered product, used as an industrial agent (pesticide). As a result of the antifungal properties, it has been demanded for commercial applications in agriculture. Antimycin is highly toxic to fish species. However, it is used in many fisheries. It has also been used as a commercial toxic agent to get rid of the unwanted fish species in catfish farms. Cross resistance analysis revealed that all mutant strains showed similar behavior against erythromycin and antimycin-A stress. Additionally, under fermentative conditions, only rapamycin affects the growth of the yeast. The aim of this study was to determine the antimicrobial resistances of some stress-resistant S. cerevisiae mutant strains and to identify possible relationships between cross-resistances to different antimicrobials and a variety of stress types. The results could be useful for future research on antibiotics and antifungals resistance.
-
ÖgeInvestigation of the localization pattern and the role of anti apoptotic BAG-1 in healthy and tumor tissues from patients with breast carcinoma(Institute of Science and Technology, 2018-06-08) Yıldız, Jale ; Doğanay Dinler, Gizem ; 521161114 ; Molecular Biology – Genetics and BiotechnologBreast cancer is the second most common cancer in world, and by far the most frequent cancer among women. In less developed region, it is the most frequent reason of death in women, and second cause of cancer death in more developed regions after lung cancer. Besides, in Turkey the most common cancer in women is breast cancer. Immunohistochemical biomarkers oestrogen receptor, progesterone receptor, human epidermal growth factor receptor and Ki-67 are considered with the combination of tumor grade, size, and nodal status for the disease status. Presently, there are 20 major types of breast cancer. However, mainly four subgroups that has been defined clearly based on gene expression profiles and molecular classification were chosen for this study: Luminal A, luminal B, HER2 enriched and triple negative breast cancers. Estrogen and progesterone receptors are steroid hormone receptors that have roles in cell growth and proliferation. PR is ligand activated transcription factor and activate signal transduction pathway in pro-proliferative signalling. It induces the activation of MAPK signalling in cell. ER induces PI3K/AKT signalling and stimulates cell growth in breast cancer cells. Besides, activated HER2 receptor phosphorylates RAS and PI3K pathways also. In nucleus, steroid hormone receptors recognise and bind to hormone responsive enhancer sequences. Bcl-2 associated anthanogene BAG-1 is commonly increased in pre-invasive breast disease and breast cancer compared to normal breast epithelium. In addition, Bag family proteins express differentially in a range of human cancers and tumour cell lines, particularly leukaemia, breast, prostate, and colon cancers. Bag family, a multifunctional group of protein that interacts with a wide range of target molecules and regulate apoptosis, proliferation, transcription, metastasis, motility and autophagy. BAG-1 also has anti-apoptotic effects, which are independent of Bcl-2; it binds to numerous receptor tyrosine kinases and improves their ability to inhibit apoptosis. Studies show that BAG-1 can be accepted as a biomarker for clinical purposes in early breast cancer prognosis. In case of breast cancer, Bag-1 is a co-chaperone for the heat-shock protein HSP70 that interacts AKT, BCL-2, B-RAF and C-RAF, steroid hormone receptors and other proteins. In the other hand, it increases estrogen dependent transcription by regulating ER function. Reported associations between BAG-1 and PR, ER are variable. To address these issues we tried to assess the expression of BAG-1 and BAG-1 related survival factors with cell lines with breast cancer that differ from the receptor type in our laboratory.Our early studies encourage us to enlighten to find out exact role of BAG-1 in survival pathway. Three isoforms of BAG-1 that are generated by alternative translation mechanism are localized various location in the cell. Bag-1 isoforms, which can be differentially localized in the cell, are functionally distinct. Alternative translation initiation from a single mRNA transcript produces 3 major and 1 minor isoform. All isoforms have BAG domain, but nuclear localization signalling is found in BAG-1L and a part of NLS in BAG-1M. Thus, BAG-1L localizes on nucleus and BAG-1M can also be translocated to nucleus. The isoforms of BAG-1 are specialized according to the tissue and cell lines they localized. Because of the involvement in number of cellular pathways, BAG-1 is regarded as an important marker for diseases, regulating cell survival. Apoptotic protein BAD is known that reside in mitochondrial membrane with dimerized with BCL-2 and BCL-XL. This dimerization promotes BAD mediated apoptosis in cell. If BAD is phosphorylated on Ser112 and Ser136 that residues are considered to be in BCL-binding site, phosphorylated BAD unable to bind mitochondrial membrane via BCL and exist cytoplasm. Cytoplasmic BAD promotes cell survival. The previous studies in our lab demonstrated that Bag-1 and its interaction partners have impprtant roles in cell survival and apoptosis pathways. The studies were managed by using tumorigenic MCF-7 and triple-negative MDA-MB-231 and non-tumorigenic MCF-10A epithelial cell lines. In our laboratory, BAG-1 interactions with p-AKT, BRAF, CRAF, BCL-2 was verified. In further, the member of this interaction complex AKT, phosphorylates BAD at Ser 136 residue and Ser 112 residue of BAD is phosphorylated via p-CRAF. The phosphorylated BAD on these two residues promotes cell survival. This work exited us to find these pathways in breast carcinoma patients' tissue. To begin with, we think about that "Are these pathways also present in tissues from breast carcinoma patients?'' and "How is the situation in breast cancer linked to hormone receptors?'' In this study, it was intended to enlighten hormone receptor and HER2 dependent expression patterns of BAG-1 and survival factors affecting BAD in breast cancer tissues. To achieve this aim, BAG-1, BAD, AKT, BRAF, CRAF and phosphorylated forms were investigated in normal and tumor breast tissues across ER, PR, HER2 status. Simultaneously, proteomic effects if the mutation in common tumor related genes were searched to identify tumor progression for same patients' sample. This study consist of two workflow, one is conducted with tissue sample from patients. Tumor tissue samples were supplied from Univesity of Ministry of Health - Umraniye Training and Research Hospital of Istanbul. Tissues were taken from the lumpectomy, mastectomy surgeons. The fresh tissues were taken into RNA Later solution. Protein isolation of both normal and tumor tissue samples were done immediately. Immunobloting studies were done further. Besides, immunohistochemistry studies were conducted. To make this experiments, tumorous sections of tissues were embedded in paraffin blocks. Formaline fixed parafine embedded tissues then stained with interested antibodies. In the other hand, we conducted NGS study to detect major common tumor suppressor and oncogenic genes variations via the genetic material isolated from the blood sample from the same patients. We conducted to library preparation step via PCR based detection kit for our breast cancer panel. Sequencing was conducted further. Aligned fragments were then analysed to searched the potential variation by using genetic tools. Many small cohort studies in literature have measured expression of BAG-1 with different outcomes in breast cancer. Researchers and clinicians found that many different results such as association between nuclear BAG-1 expression and decreased survival or association between high cytoplasmic Bag-1 and improved survival. However the estrogen, progesterone, human epidermal growth factor receptor and Bag-1 interactions came up as an important issue. Also, described associations between Bag-1, ER and PR are different. Some studies have shown no association between Bag-1 expression and ER or PR expression while other studies have shown that Bag-1 and ER tend to co-express, as do BAG-1 and PR. There are many contradictions about it. Total forty eight tissue samples from different patients were used to make protein experiments in this study. The main finding in this study is that in tumors, BAG-1 L overexpression accompanied by BAG-1 localization in nucleus. Besides, ER positivity is parallel for this relationship. In lumainal A type, BAG-1L, p-AKT and p-BAD Ser 136 resided in nucleus. Depends on the finding, we suggested that possible BAG-1, p-AKT, BAD/p-BAD Ser 136 triple complex might be co-localized in nucleus in the condition of ER presence and BAG-1L could be the main target for the ER-related breast tumors.